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2 
ABSTRACT 23 
Development of a prophylactic vaccine for hepatitis C virus (HCV) remains a global health 24 
challenge. Cumulative evidence supports the importance of antibodies targeting the HCV E2 25 
envelope glycoprotein to facilitate viral clearance. However, a significant challenge for a B 26 
cell-based vaccine is focusing the immune response on conserved E2 epitopes capable of 27 
eliciting neutralizing antibodies not associated with viral escape. We hypothesized that 28 
glycosylation might influence the antigenicity and immunogenicity of E2. Accordingly, we 29 
performed head-to-head molecular, antigenic and immunogenic comparisons of soluble E2 30 
(sE2) produced in (i) mammalian (HEK293) cells, which confer mostly complex and high 31 
mannose type glycans; and (ii) insect (Sf9) cells, which impart mainly paucimannose type 32 
glycans. Mass spectrometry demonstrated that all 11 predicted N-glycosylation sites were 33 
utilized in both HEK293- and Sf9-derived sE2, but that N-glycans in insect sE2 were on 34 
average smaller and less complex. Both proteins bound CD81 and were recognized by 35 
conformation-dependent antibodies. Mouse immunogenicity studies revealed that similar 36 
polyclonal antibody responses were generated against antigenic domains A–E of E2. 37 
Although neutralizing antibody titers showed that Sf9-derived sE2 induced moderately 38 
stronger responses than HEK293-derived sE2 against the homologous HCV H77c isolate, 39 
the two proteins elicited comparable neutralization titers against heterologous isolates. Given 40 
that global alteration of HCV E2 glycosylation by expression in different hosts did not 41 
appreciably affect antigenicity or overall immunogenicity, a more productive approach to 42 
increasing the antibody response to neutralizing epitopes may be complete deletion, rather 43 
than just modification, of specific N-glycans proximal to these epitopes.   44 
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IMPORTANCE 45 
Development  of a vaccine for hepatitis C virus (HCV) remains a global health 46 
challenge. A major challenge for vaccine development is focusing the immune response on 47 
conserved regions of the HCV envelope protein, E2, capable of eliciting neutralizing 48 
antibodies. Modification of E2 by glycosylation might influence the immunogenicity of E2. 49 
Accordingly, we performed molecular and immunogenic comparisons of E2 produced in 50 
mammalian and insect cells. Mass spectrometry demonstrated that the predicted 51 
glycosylation sites were utilized in both mammalian and insect cell E2, although the glycan 52 
types in insect cell E2 were smaller and less complex. Mouse immunogenicity studies 53 
revealed similar polyclonal antibody responses. However, insect cell E2 induced stronger 54 
neutralizing antibody responses against the homologous isolate used in the vaccine, albeit 55 
the two proteins elicited comparable neutralization titers against heterologous isolates. A 56 
more productive approach for vaccine development may be complete deletion of specific 57 
glycans in the E2 protein.  58 
 59 
INTRODUCTION 60 
 Hepatitis C virus (HCV) is a major public health problem and infects over 71 million 61 
people worldwide (1). Infection often develops into chronic hepatitis, which is the most 62 
prevalent cause of liver failure and hepatocellular carcinoma. In recent years, new direct 63 
acting antivirals (DAAs) have supplanted the use of ribavirin and pegylated interferon alpha 64 
as a treatment regimen, reaching cures rates of greater than 90% in HCV genotype 1-infected 65 
patients (2, 3). However, significant limitations still exist, including the high cost of DAAs 66 
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4 
that restricts access in developing countries where the disease burden is greatest (3) and 67 
concerns about the development of drug resistance (2, 3). Moreover, therapy-induced HCV 68 
clearance does not provide immunity to new infections or eliminate the risk of hepatocellular 69 
carcinoma in patients with established cirrhosis. Therefore, an effective preventative vaccine 70 
is an important medical and public health need (4).  71 
 The genetic diversity of HCV of at least seven genotypes that differ up to 30% in 72 
nucleotide sequence poses a major challenge to developing a pan-genotypic vaccine. HCV is 73 
composed of a nucleocapsid core enveloped by a lipid bilayer in which two surface 74 
glycoproteins, E1 and E2, are anchored. During acute infection, a robust neutralizing 75 
antibody response correlates with spontaneous resolution of infection (5, 6). Most broadly 76 
neutralizing antibodies (bNAbs) recognize conformational epitopes in E2 and some in E1E2 77 
(7, 8). Passive immunization with anti-HCV antibodies before HCV challenge can prevent 78 
infection against homologous virus challenge in animal models (9, 10), although virus 79 
breakthrough can occur and protection against heterologous virus strains remains a problem. 80 
Other complicating factors for vaccine development include low immunogenicity of viral 81 
envelope proteins and antibody responses directed to regions that display a high mutational 82 
rate of change (11). In addition, a number of studies have highlighted the role of N-linked 83 
glycosylation in masking or shielding E2 epitopes from recognition by bNAbs (12-16), as 84 
also observed for HIV and influenza virus (17). Such glycan shielding may hinder bNAb 85 
induction by reducing the exposure of neutralizing epitopes to the humoral immune system, 86 
further complicating development of a B cell-based HCV vaccine.    87 
 There is evidence from a number of studies, mainly involving HIV and influenza, that 88 
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5 
alteration of glycans on viral envelope glycoproteins can impact immune recognition and 89 
immunogenicity. Some studies have used hyperglycosylation, the addition of N-glycans 90 
through mutagenesis to create glycan sequons, to mask certain sites associated with 91 
non-neutralizing antibodies and antibody escape (18-22). Conversely, targeted removal of 92 
glycans through mutagenesis of glycan sequons has been used to improve or alter 93 
neutralizing antibody engagement of key epitopes for HIV-1 (23-26), influenza A virus (27), 94 
and HCV (13-15). For example, in one study, elimination of glycosylation sites in the 95 
vicinity of the CD4-binding site of the HIV-1 envelope glycoprotein (Env) generated an 96 
immunogen that more efficiently activated B cells expressing germline precursors of bNAbs 97 
(25). However, in another study, targeted deglycosylation of HIV-1 Env failed to generate an 98 
antigen capable of eliciting neutralizing antibodies against wild-type viruses in immunized 99 
guinea pigs or rhesus macaques (28). In the case of influenza A virus, removal of glycans in 100 
the hemagglutinin (HA) protein that shield key epitopes of HA from antibody recognition 101 
produced immunogens that elicited bNAbs effective against antigenically distant virus 102 
strains (27). In the case of HCV, deletion of specific glycans in HCV E1E2 was found to 103 
modulate binding of certain bNAbs (14, 15), although the immunogenicity of these modified 104 
E1E2 proteins was not studied. 105 
 An alternate strategy to modulate presentation of key antibody epitopes is 106 
modification of the extent of glycosylation through the use of various expression cell types 107 
(29-32), or enzymatic truncation of glycoforms (33). In one study, HIV-1 gp120 was 108 
produced in Spodoptera insect (Sf9) cells, which impart mainly paucimannose type glycans, 109 
and in mammalian (HEK293) cells treated with the -mannosidase inhibitor kifunensine, 110 
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which confers only high mannose type glycans (30). These global alterations in 111 
glycosylation compared to gp120 produced in untreated HEK293 cells led to increased 112 
exposure of the CD4 binding site, which encouragingly translated to increased binding of 113 
bNAbs specific for this site. However, the effect on HIV-1 neutralization titers in animals 114 
immunized with these modified gp120 glycoproteins was not reported. More recently, a 115 
secreted, soluble form of HCV E2 (sE2) produced in Drosophila insect (S2) cells was found 116 
to be more immunogenic than the corresponding protein produced in HEK293 cells (31). 117 
Moreover, S2-derived sE2 elicited higher titers of antibodies capable of neutralizing a 118 
diverse panel of HCV genotypes, suggesting that distinct glycosylation patterns should be 119 
taken into consideration in development of a recombinant HCV vaccine.  120 
 To further test the hypothesis that differential glycosylation may influence the 121 
antigenicity and immunogenicity of E2, we performed head-to-head molecular, antigenic 122 
and immunogenic comparisons of sE2 produced in (i) mammalian (HEK293) cells, which 123 
impart high mannose, hybrid and complex glycans; and (ii) insect (Sf9) cells, which confer 124 
mainly paucimannosidic glycans. In contrast to Li et al. (31), we found that immunization of 125 
mice with mammalian and insect sE2 glycoproteins elicited comparable antibody 126 
neutralization titers against heterologous HCV isolates, although Sf9-derived sE2 was a 127 
more potent immunogen against the homologous H77c isolate. We discuss possible reasons 128 
for the apparent discrepancy between our results and theirs, and conclude that targeted 129 
deletion of specific E2 glycans, rather than expression system-dependent modification of all 130 
glycans, may be a better strategy for increasing the exposure of virus neutralizing epitopes to 131 
the humoral immune system. 132 
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 133 
MATERIALS AND METHODS  134 
 Protein expression, purification, and antibodies.  For mammalian cell expression, a 135 
gene encoding HCV E2 from strain 1a H77c (residues 384–661) was cloned into the vector 136 
pSecTag2 (Invitrogen) with an N-terminal immunoglobulin  light chain signal sequence (for 137 
secretion) and a C-terminal His6 tag (for purification). The construct was transfected with 138 
293fectin into FreeStyle HEK293-F cells (Invitrogen). Recombinant monomeric E2 was 139 
purified from culture supernatants by sequential HisTrap Ni2+-NTA and Superdex 200 columns 140 
(GE Healthcare). For insect cell expression, the same E2 sequence was fused to the gp67 141 
secretion signal sequence of baculovirus vector pAcGP67-B (BD Biosciences) with a 142 
C-terminal His6 tag. To generate recombinant baculovirus, this construct was transfected into 143 
Sf9 cells together with BaculoGold Linearized DNA (BD Biosciences). Soluble monomeric E2 144 
was purified from culture supernatants of Sf9 cells infected with recombinant baculovirus 145 
using sequential HisTrap Ni2+-NTA and Superdex 200 columns. 146 
 Human CD81 large extracellular loop (CD81-LEL; CD81 residues 113–201) coding 147 
sequence DNA was synthesized (GenScript) and cloned into the vector pHLsec (Addgene 148 
plasmid #99845; a gift from E. Yvonne Jones) which includes a C-terminal His6 tag. The 149 
construct was transfected with PEI MAX 40K (Polysciences) into FreeStyle HEK293-F cells. 150 
CD81-LEL was purified from culture supernatant by sequential HiTrap Chelating HP 151 
Ni2+-NTA and Superdex 75 columns (GE Healthcare). Before biolayer interferometry, purified 152 
CD81-LEL was stripped of its C-terminal His6 tag by digestion with carboxypeptidase 153 
A-agarose (Sigma). 154 
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 Monoclonal antibody HCV1 was kindly provided by Dr. Yang Wang (MassBiologics, 155 
University of Massachusetts Medical School) (37). Monoclonal antibodies against different 156 
antigenic domains, CBH-4B and CBH-4G (domain A), HC-1 and HC-11 (domain B), CBH-7 157 
(domain C), HC84.24 and HC84.26 (domain D), and HC33.1 and HC33.4 (domain E) were 158 
employed and prepared as described (7).  159 
 Mass spectrometry.  Digestion was performed on 80 µg each of HEK293- and 160 
Sf9-derived sE2 by denaturing using 6 M guanidine HCl, 1 mM EDTA in 0.1 M Tris, pH 7.8, 161 
reduced with a final concentration of 20 mM DTT (65 oC for 90 min), and alkylated at a final 162 
concentration of 50 mM iodoacetamide (room temperature for 30 min). Samples were then 163 
buffer exchanged into 1 M urea in 0.1 M Tris, pH 7.8 for digestion. Sequential digestion was 164 
performed using trypsin (1/50 enzyme/protein ratio, w/w) for 18 hours at 37oC, followed by 165 
chymotrypsin (1/20 enzyme:protein, w/w) with 10 mM CaCl2 overnight at room temperature. 166 
LC-UV-MS analyses were performed using an UltiMate 3000 LC system coupled to an LTQ 167 
Orbitrap Elite equipped with a heated electrospray ionization (HESI) source and operated in a 168 
top 5 dynamic exclusion mode. A volume of 30 l (representing 9 g of digested protein) of 169 
sample was loaded via the autosampler onto a C18 peptide column (AdvanceBio Peptide 2.7 170 
um, 2.1 x 150 mm, Agilent part number 653750-902) enclosed in a thermostatted column oven 171 
set to 50 °C. Samples were held at 6 °C while queued for injection. The chromatographic 172 
gradient was conducted as described in Table 1. Glycan and glycopeptide identification was 173 
performed using Byonic software and extracted ion chromatograms used for quantification of 174 
glycoforms in Byologic software (Protein Metrics).   175 
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  Glycoprotein modeling.  Glycans were modeled on the E2 protein structure using 176 
Rosetta software (34). Prior to glycan modeling, residues from antigenic domain E were 177 
modeled into the structure of E2 core (Protein Data Bank accession code 4MWF) (35) and 178 
refined using the FloppyTail method in Rosetta (36). The most abundant glycan at each site 179 
was encoded as an IUPAC string and modeled on E2 core using the SimpleGlycosylateMover 180 
in Rosetta, followed by the glycan_relax protocol to alleviate clashes involving glycans and 181 
energetically unfavorable conformations (using command line flags "-tree_based_min_pack 182 
-glycan_relax_refine"). Accessible surface area calculations were performed in Rosetta using 183 
the TotalSasa filter, specifying the probe radius using the "-sasa_calculator_probe_radius" 184 
command line flag. Percent E2 surface masking by glycans was calculated by dividing the 185 
surface accessibility of protein residues in the glycosylated E2 model by the surface 186 
accessibility of protein residues in the same model with all glycans removed. Structural 187 
visualization was performed in Pymol (www.pymol.org). 188 
 Biolayer interferometry. The interaction of sE2 derived from HEK293 or Sf9 cells 189 
with CD81 and human monoclonal antibodies (HMAbs) in IgG format specific for antigenic 190 
domains A (CBH-4B, CBH-4G), B (HC-1, HC-11), D (HC84.26, HC84.24), and E (HCV1, 191 
HC33.1) (7, 37) was measured using an Octet RED96 instrument and Ni2+-NTA biosensors 192 
(Pall ForteBio). The biosensors were loaded with 5 g/mL of purified His6-tagged sE2 for 193 
600 sec, then stabilized with the chemical crosslinker mixture of 0.1 M 194 
1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide and 0.025 M N-hydroxysuccinimide (GE 195 
Life Sciences) for 60 seconds followed by reaction quenching with 1 M ethanolamine, pH 196 
8.0 for 60 sec. Association for 300 sec followed by dissociation for 300 sec against a 2-fold 197 
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10 
concentration dilution series of each antibody was performed. Data analysis was performed 198 
using Octet Data Analysis 10.0 software and utilized reference subtraction at 0 nM antibody 199 
concentration, alignment to the baseline, interstep correction to the dissociation step, and 200 
Savitzky-Golay fitting. Curves were globally fitted based on association and dissociation to 201 
obtain KD values.  202 
  Animal immunization.  CD-1 mice were purchased from Charles River. Prior to 203 
immunization, sE2 antigens were formulated with SAS adjuvant (Sigma Adjuvant System, 204 
Sigma Aldrich) at a 1:1 ratio according to the manufacturer’s instructions. On scheduled 205 
vaccination days, groups of 6 female mice, age 7–9 weeks, were injected via the 206 
intraperitoneal (IP) route with a 50 µg sE2 prime (day 0) and boosted with 10 µg sE2 on days 207 
7, 14, 28, and 35. Blood samples were collected prior to each injection with a terminal bleed 208 
on day 49. The collected samples were processed for serum by centrifugation and stored at 209 
-80 °C until analysis was performed. 210 
 Competitive binding ELISA.  An ELISA measured the inhibition by mouse sera of 211 
HMAb binding to E2 glycoproteins captured by Galanthus nivalis lectin (GNA) (38). 212 
Briefly, microtiter plates were coated with GNA and blocked with 2.5% bovine serum 213 
albumin (BSA) and 2.5% normal goat serum in 0.1% Tween-PBS, prior to the addition of 2 214 
µg/well of HEK293 sE2. Pretitrated mouse serum was added to each well at a saturating 215 
concentration. After 1 h, HMAb was added at a concentration corresponding to 65% to 75% 216 
of the maximal optical density (OD) level, incubated for 30 min at either room temperature 217 
or 40 °C, and then washed. Bound HMAb was detected by incubation with alkaline 218 
phosphatase-conjugated goat anti-human IgG (Promega), followed by incubation with 219 
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11 
p-nitrophenyl phosphate (Sigma) for color development. Absorbance was measured at 220 
405/570 nm. This assay was carried out in triplicate, a minimum of two times for each 221 
HMAb. 222 
 Cell lines and pseudoparticle plasmid construction.  The human embryonic 223 
kidney 293T (HEK293T) and Hep3B cells were purchased from ATCC (www.atcc.org). 224 
Both HEK293T and Hep3B cells were grown in Dulbecco’s modified essential medium 225 
(DMEM) (Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS) and 226 
1% penicillin-streptomycin (Thermo Fisher Scientific). The human hepatoma cell line, 227 
HuH7 was purchased from ECACC and routinely tested for mycoplasma contamination. 228 
HuH7 cells were grown in Dulbecco’s modified essential medium (DMEM) (Thermo Fisher 229 
Scientific) supplemented with 10% fetal bovine serum (FBS) and 1% non-essential amino 230 
acids (NEAA) (Thermo Fisher Scientific). All were maintained in a humidified 37 °C, 5% 231 
CO2 incubator. The different genotype constructs for gt1a (H77c, UNKP1.1.1), gt1b 232 
(UNKP1.20.3, UNKP1.21.2), gt2a (J6, JFH), gt2b (UNKP2.4.1), gt2i (UNKP2.1.2), gt3 233 
(UNKP3.2.2), gt4 (UNKP4.2.1), gt5 (UNKP5.1.1), and gt6 (UNKP6.1.1) were described 234 
previously (39, 40). The MLV Gag-Pol packaging vector (phCMV-5349) and luciferase 235 
reporter plasmid (pTG126) have been reported (40). All plasmids were grown and purified 236 
using the EndoFree Plasmid Maxi Kit (Omega Bio-tek). Concentration and purity were 237 
verified by restriction analysis, sequencing and spectrophotometry. 238 
 Pseudoparticle generation and titration.  HCV pseudoparticles (HCVpp) were 239 
generated by co-transfection of HEK293T cells with the MLV Gag-Pol packaging vector, 240 
luciferase reporter plasmid, and plasmid expressing HCVE1E2 using Lipofectamine 3000 241 
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12 
(Thermo Fisher Scientific) as described previously (40). No-envelope control (empty 242 
plasmid) was used as negative control in all experiments. Supernatants containing 243 
HCVE1E2 pseudoparticles were harvested at 48 h and 72 h post-transfection, and filtered 244 
through 0.45 m pore-sized membranes. The generated HCVpp is capable of achieving a 245 
single-round infection in Hep3B or HuH7 target cells and contains a luciferase reporter gene 246 
that can be expressed in infected cells. Titration of HCVpp was then determined by infecting 247 
Hep3B cells with a serial dilution.  248 
 HCVpp neutralization assays.  For infectivity and neutralization testing of HCVpp, 249 
either 104 Hep3B cells per well or 1.5 x 104 HuH7 cells per well were plated in white 96-well 250 
tissue culture plates (Corning) and incubated overnight at 37 °C. The following day, HCVpp 251 
were mixed with appropriate amounts of antibody and then incubated for 1 h at 37 °C before 252 
adding to Hep3B or HuH7 cells. After 72 h at 37 °C, either 100 l Bright-Glo (Promega) was 253 
added to each well and incubated for 2 min or cells were lysed with Cell lysis buffer 254 
(Promega E1500) and placed on a rocker for 15 min. Luciferase activity was then measured 255 
in relative light units (RLUs) using either a SpectraMax M3 microplate reader (Molecular 256 
Devices) with SoftMax Pro6 software (Bright-Glo protocol) or wells were individually 257 
injected with 50uL luciferase substrate and read using a FLUOstar Omega plate reader 258 
(BMG Labtech) with MARS software. Infection by HCVpp was measured in the presence of 259 
anti-HCV E2 MAbs, tested animal sera, pre-immune animal sera, and non-specific IgG at the 260 
same dilution. Each sample was tested in duplicate or triplicate. Neutralizing activities were 261 
reported as 50% inhibitory dilution (ID50) values and were calculated by nonlinear regression 262 
(Graphpad Prism Version 7), using lower and upper bounds (0% and 100% inhibition) as 263 
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13 
constraints to assist curve fitting. 264 
 Statistical analysis.  Comparison of neutralization titers between groups (ID50 265 
values; Figures 8 and 9) was performed using Kruskal-Wallis ANOVA with Dunn's multiple 266 
comparison test. Data analysis was not blinded. Differences were considered statistically 267 
significant at p < 0.05. Comparison of serum antibody percent E2 binding competition 268 
between groups (Figure 7) was performed using t-test. Statistical analyses were performed 269 
using GraphPad Prism 7 software. 270 
 271 
RESULTS 272 
 Expression of soluble HCV E2 glycoprotein in HEK293 and Sf9 cells.  In order to 273 
investigate the effect of different glycosylation patterns on the antigenicity and 274 
immunogenicity of HCV E2, we produced a soluble form of E2 (sE2) lacking the 275 
hydrophobic C-terminal transmembrane anchor in mammalian (HEK293) and insect (Sf9) 276 
cells, which are known to attach different N-glycan moieties to proteins (42, 43). For 277 
expression of sE2 in HEL293 cells, a DNA fragment encoding amino acids 384–661 of strain 278 
1a HCV H77c polyprotein was cloned into the pSecTag2 vector under control of the CMV 279 
promoter. The same DNA fragment was used for expression of sE2 in Sf9 insect cells using 280 
the pAcGP67-B vector in which expression is controlled by the polyhedrin promoter (Figure 281 
1A). Secreted, monomeric sE2 proteins bearing C-terminal His6 tags were purified from 282 
culture supernatants by immobilized Ni2+ affinity chromatography, followed by size 283 
exclusion chromatography. Superdex 200 elution profiles for HEK293- and Sf9-dervied sE2 284 
showed that both proteins formed oligomers and high molecular aggregates, in addition to 285 
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14 
monomers (Figure 1B and C). In both cases, we isolated the peak corresponding to 286 
monomeric sE2. Only monomeric HEK293- and Sf9-dervied sE2 proteins were used for all 287 
subsequent analytical and immunological experiments. As shown in Figure 1D, the 288 
HEK293- and Sf9-derived sE2 proteins migrated in non-reducing SDS-PAGE at apparent 289 
molecular weights of ~75 kDa and ~40 kDa, respectively, compared to a calculated 290 
molecular weight of ~34 kDa based on primary amino acid sequence. Thus, sE2 is 291 
glycosylated differently by mammalian and insect cells, as expected (42, 43). In addition, we 292 
examined HEK293- and Sf9-derived sE2 in SDS-PAGE under reducing conditions and 293 
carried out Western blot analysis using HMAb HC33.1 (Figure 1E). HC33.1 recognizes a 294 
linear epitope of HCV E2 (domain E) comprising residues 412–423 (7). The Western blot 295 
revealed major bands at ~60 kDa and ~40 kDa for reduced HEK293- and Sf9-derived sE2, 296 
respectively, which is similar to what was observed under non-reducing conditions (Figure 297 
1D). There was no indication of significant proteolysis of either HEK293- or Sf9-derived 298 
sE2 (Figure 1E). Moreover, reactivity with HC33.1 confirmed the identity of both purified 299 
proteins as HCV E2. We therefore conclude that Sf9-derived sE2 is intact and not more 300 
susceptible to proteolysis than HEK293-derived sE2, despite differences in glycosylation. To 301 
pinpoint these differences, we used mass spectrometry (MS) to identify the nature of sugars 302 
attached to HEK293- and Sf9-dervied sE2.  303 
 N-glycosylation analysis of HCV E2 expressed in HEK293 and Sf9 cells.  Three 304 
major types of mature N-glycans may be attached to glycoproteins such as HCV E2 305 
produced in mammalian cells: (i) high mannose glycans, consisting of up to six mannose 306 
(Man) residues attached to a trimannosyl chitobiose core (Man3GlcNAc2); (ii) complex type 307 
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glycans, composed primarily of N-acetylglucosamine (GlcNAc) and galactose (Gal) 308 
residues attached to the Man3GlcNAc2 core, with or without sialic acid (NeuAc) residues, 309 
where a fucose (Fuc) residue may be added to the first GlcNAc of the core; and (iii) hybrid 310 
type glycans, which consist of Man and lactosamine (GlcNAcGal) residues, with or without 311 
NeuAc, attached to the Man3GlcNAc2 core (42, 43). Insect expression systems, on the other 312 
hand, commonly express paucimannose structures as well as core 1,3 fucosylation absent in 313 
mammalian expression systems.  314 
 We used MS to characterize the glycan moieties attached to the 11 potential 315 
N-glycosylation sites of HCV E2 derived from HEK293 and Sf9 cells. The composition and 316 
microheterogeneity of the glycans attached to each N-linked site were determined by 317 
LC-UV-MS/MS analyses of enzymatic digests (trypsin and chymotrypsin sequential digest) 318 
of reduced and alkylated HEK293- and Sf9-derived sS2. Glycopeptide identifications were 319 
made based on MS/MS fragmentation, followed by relative abundance calculation using 320 
extracted ion chromatograms of the parent ion. Representative MS spectra of glycopeptide 321 
447–455 of HEK293- and Sf9-derived sE2 are shown in Figure 2. Doubly charged 322 
glycopeptides observed above 1% relative abundance are depicted to demonstrate the 323 
general trend of glycans of larger composition observed in HEK293-derived sE2. A complete 324 
list of the glycan compositions identified at each glycosylation site of HEK293-derived 325 
versus Sf9-derived sE2, as well as the corresponding glycan populations down to 0.1% 326 
relative abundance based on extracted ion chromatograms of the parent ions, is presented in 327 
Supplementary Table 1. These 11 glycosylation sites are located at E2 positions 417 328 
(designated N1), 423 (N2), 430 (N3), 448 (N4), 476 (N5), 532 (N6), 540 (N7), 556 (N8), 576 329 
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(N9), 623 (N10), and 645 (N11).  330 
 Multiple complex and high mannose type glycans were identified at 11 of 11 331 
N-linked sites of HEK293-derived sE2 (Supplementary Table 1). As expected for a 332 
glycoprotein expressed in insect cells (42, 43), the major glycoforms present on Sf9-derived 333 
sE2 were paucimannose N-glycans, with or without one or two core Fuc residues. Complex 334 
N-glycans were detected at all sites except N7 in Sf9-derived sE2, albeit with a lower degree 335 
of extension and branching on average than in HEK293-derived sE2. Complex type glycans 336 
accounted for only 1–10% of the total identified N-glycans in Sf9-derived sE2 337 
(Supplementary Table 1). The most abundant glycoform at each site observed in LC-MS 338 
analysis of HEK293- and Sf9-derived sE2 is depicted in Figure 3.  339 
 For both HEK293- and Sf9-derived sE2, the same nine N-glycan sites are near fully 340 
(>95%: N1, N2, N4, N5, N6, N8 and N9) or highly (>75%: N3 and N7) glycosylated (Figure 341 
4). Of note, the two exceptions (N10 and N11) exhibit relatively low levels of glycan 342 
occupancy in both mammalian and insect cell-derived sE2. This concordance in extent of 343 
glycosylation for sE2 from two hosts with significantly different protein N-glycosylation 344 
pathways suggests that factors intrinsic to E2 itself, such as differential accessibility of 345 
individual glycosylation sites to the cellular N-glycosylation biosynthetic machinery, may 346 
explain the observed site-specific differences in percent glycosylation (Figure 4).  347 
 Molecular modeling of N-glycosylation sites.  To compare the structural impact of 348 
N-glycosylation in sE2 derived from HEK293 versus Sf9 cells, we modeled the most 349 
abundant glycoform at each site on the E2 core structure (Figure 5). This analysis 350 
highlighted the differential glycan sizes observed in the two expression systems, particularly 351 
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those proximal to key epitopes such as N6 (Figure 5A and B), which is adjacent to the 352 
ARC3 binding site in antigenic domain B (7) and is markedly larger for HEK293- versus 353 
Sf9-expressed sE2. These models were used to calculate protein surface occlusion from 354 
glycosylation (Table 2). Though a solvent-sized probe (1.4 Å radius) detected little 355 
difference between E2 surface occlusion in the models, larger probe radii (5 and 10 Å), 356 
which are more representative of antibody complementarity-determining region (CDR) 357 
loops, revealed relatively high E2 occlusion (40–65% of the protein surface), with 358 
HEK293-derived sE2 having somewhat higher levels of masked surface than Sf9-derived 359 
sE2 (9% higher for 10 Å probe). This is similar to previous observations comparing 360 
glycosylation of HEK293- versus Sf9-expressed HIV gp120, where approximately 10% 361 
greater surface occlusion for HEK293-expressed gp120 was calculated using a 10 Å probe 362 
radius (30). However, it should be noted that this analysis does not include E2 regions 363 
missing from the crystal structure (e.g. HVR1), E2 dimerization with E1, and conformational 364 
mobility of glycans and E2 residues. Nevertheless, the calculated 9% reduction in protein 365 
surface coverage imparted by the Sf9 cell production system could potentially affect the 366 
exposure of antibody binding sites proximal to glycans.  367 
  CD81 binding and antigenicity of HCV E2 expressed in mammalian versus 368 
insect cells.  To determine whether differential glycosylation affected binding to the CD81 369 
entry receptor, we used biolayer interferometry (BLI) to measure the affinity of HEK293- 370 
and Sf9-derived sE2 for recombinant CD81 (Figures 6A and B). Purified sE2 proteins were 371 
directionally coupled to a Ni2+-NTA biosensor surface through their C-terminal His6 tags. 372 
HEK293-derived sE2 bound CD81 with a KD of 510 nM compared to 440 nM for 373 
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Sf9-derived sE2 (Table 3). These very similar KD values demonstrate that both glycoproteins 374 
are functional with respect to entry receptor binding. Moreover, this result indicates that the 375 
proteins are properly folded since alanine-scanning mutagenesis has shown that the CD81 376 
binding site comprises residues from several non-contiguous segments of the E2 polypeptide 377 
chain (i.e. it is conformational in nature) (7, 8). 378 
 To determine whether differential glycosylation affected epitope presentation, we 379 
used BLI to measure the binding of HEK293- and Sf9-expressed sE2 to a panel of eight 380 
HMAbs targeting four antigenic domains on E2: CBH-4B and CBH-4G (domain A), HC-1 381 
and HC-11 (domain B), HC84.26 and HC84.24 (domain D), and HCV1 and HC33.1 (domain 382 
E) (7, 37) (Figure 6C–L). Of note, this provides a direct comparative view of 293- versus 383 
Sf9-expressed sE2, while absolute measured affinity (KD) values may reflect effects of 384 
bivalent IgG binding. Five of these HMAbs bound both sE2 proteins with very similar KDs, 385 
all in the nanomolar range: HC84.26 (1.8 nM for HEK293-derived sE2; 2.7 nM for 386 
Sf9-derived sE2), HCV1 (36 and 9.3 nM), HC33.1 (50 and 47 nM), HC-1 (65 and 69 nM), 387 
and HC-11 (7.0 and 25 nM) (Table 3). Importantly, the ability of conformation-dependent 388 
HMAbs HC84.26, HC-1, and HC-11 (7) to recognize both versions of sE2 with high affinity 389 
indicates that both glycoproteins are correctly folded, in agreement with our CD81 binding 390 
results. The other three HMAbs bound HEK293-derived sE2 more tightly than Sf9-derived 391 
sE2: HC84.24 (1.9 nM for HEK293-derived sE2; 1200 nM for Sf9-derived sE2), CBH-4B 392 
(11 and 120 nM), and CBH-4G (120 nM for HEK293-derived sE2; no apparent binding to 393 
Sf9-derived sE2) (Table 3). We attribute these affinity differences to differential 394 
glycosylation, given that glycans cover ~50% of the surface of sE2 (Figure 2) and so are 395 
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likely to influence HMAb binding to at least some epitopes, either directly or indirectly (see 396 
Discussion). These results demonstrate that increasing protein surface exposure by reducing 397 
glycan size did not translate into enhanced antigenicity, at least for the eight HMAbs tested 398 
here.  399 
 Immunization of mice with sE2 induces serum antibodies that recognize 400 
broadly neutralizing epitopes.  To compare the antibody responses in mice immunized 401 
with the HEK293- and Sf9-derived sE2 proteins, groups of CD-1 mice (n=5) were 402 
immunized with 50 g of purified protein formulated in SAS adjuvant (oil-in-water 403 
emulsion), followed by four 10 g boosts over a course of five weeks. Serum samples were 404 
collected one week after the fifth immunization (D=42), and sera tested for epitope-specific 405 
responses by competitive binding ELISA using HMAbs derived from HCV-infected 406 
individuals that represent the five antigenic domains of E2 (7-10): CBH-4B (domain A), 407 
HC-1 (domain B), CBH-7 (domain C), HC84.26 (domain D), and HC33.3 (domain E) 408 
(Figure 7). Based on binding competition, antibodies were elicited to all five antigenic 409 
domains in both groups of mice. Both groups had relatively high levels of serum competition 410 
with the antigenic domain B HMAb HC-1; this domain is associated with broadly 411 
neutralizing antibodies and overlaps with the CD81 binding site (7). Comparing the two 412 
groups of immunized mice, no significant differences were observed for domain-specific 413 
serum antibody competition (t-test, GraphPad Prism 7).  414 
 Viral neutralization against homologous and heterologous isolates of HCV.  In 415 
order to assess the relative potency of the HEK293- and Sf9-derived sE2 immunogens, 416 
mouse sera were tested for neutralizing antibody (nAb) titers against homologous and 417 
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heterologous isolates of HCV E1E2 using the HCVpp neutralization assay. The values are 418 
expressed as serum dilution levels corresponding to 50% neutralization (ID50). As shown in 419 
Figure 8, the mean ID50 values of nAb against the homologous isolate (H77c) (i.e. same 420 
E1E2 sequences as used in the vaccine) were 5-10 fold higher for Sf9-derived versus 421 
HEK293-derived sE2 after the third (D=28), fourth (D=35), and fifth (D=42) immunizations, 422 
with significant differences between groups at Days 28 and 42. However, the difference 423 
diminished two weeks after the last immunization (D=49) to give approximately the same 424 
values.   425 
 To assess the breadth of neutralization, mouse sera (Day 49) were subsequently 426 
tested against a diverse panel of six HCV genotypes: gt1a, gt1b, gt2a, gt2b, gt2i, gt3a, gt4a, 427 
gt5a, and gt6a, as previously described (40). As shown in Figure 9, animals immunized with 428 
both HEK293- and Sf9-derived sE2 were able to elicit bNAbs against all of the HCVpps 429 
tested in the panel, although genotypes 1a and 1b had the highest ID50 titers overall. The ID50 430 
values against the homologous H77c isolate were moderately, though not significantly, 431 
higher for Sf9-derived sE2. This confirms the relative H77c neutralization titers observed at 432 
this timepoint in Figure 8, which was performed separately using different target cells 433 
(Hep3B cells, versus HuH7 cells for Figure 9). For most of the other isolates, there were 434 
modest, though insignificant increases of ID50s for the HEK293 sE2 immunized group, with 435 
the exception of the J6 isolate where a significant increase for the HEK293 sE2 titers was 436 
observed. It is possible that this modest decrease in breadth could be due to a more 437 
pronounced nAb response to HVR1 or other variable regions induced by Sf9-expressed sE2 438 
versus HEK293-expressed sE2. HVR1 has been reported as an immunodominant site for 439 
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nAbs, although the nAb response is largely strain-specific (44-47). Therefore, the lower level 440 
of ID50 values for the other heterologous HCVpp genotypes may reflect lack of nAb 441 
cross-recognition of the HVR1 sites due to sequence variation in this region.  442 
 443 
DISCUSSION 444 
  In this study, we asked whether reducing the overall glycosylation of HCV sE2 (gt1a, 445 
H77) by producing this protein in Spodoptera insect (Sf9) cells improved its antigenicity 446 
and/or immunogenicity compared to sE2 produced in mammalian (HEK293) cells. Mass 447 
spectrometry showed that all 11 predicted N-glycosylation sites were utilized in sE2 from 448 
both HEK293 and Sf9 cells. Although most sites were fully or nearly fully glycosylated, two 449 
sites (N10 and N11) showed low (<50%) glycan occupancy. As expected, N-glycans in 450 
insect sE2 were, on average, smaller and less complex than N-glycans in mammalian sE2.  451 
  After modeling the most abundant glycoform at each site on the E2 structure (35), we 452 
quantified glycan coverage by calculating the amount of protein surface exposed to a 453 
spherical probe the size of an antibody binding site. Our analysis revealed that 64% of the 454 
surface of HEK293-derived sE2 was occluded by N-glycans compared to 55% for 455 
Sf9-derived sE2, corresponding to a 9% reduction in glycan shielding in insect 456 
cell-expressed material. However, this reduction was not associated with improved HMAb 457 
binding (Table 3). The ability of CD81, HC84.26, HCV1, HC33.1, HC-1 and HC-11 to bind 458 
HEK293- and Sf9-derived sE2 equally well indicates that E2 recognition by these six ligands 459 
does not require complex type glycans.  460 
 o
n
 January 25, 2019 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
22 
  By contrast, HC84.24, CBH-4B and CBH-4G bound Sf9-derived sE2 less well than 461 
HEK293-derived sE2. It is not particularly surprising that some HMAbs bind these two 462 
glycoproteins with different KDs given that: 1) Sf9- and HEK293-derived sE2 are 463 
glycosylated quite differently; 2) glycans cover ~50% of the surface of E2 (Figure 5) and so 464 
are likely to influence HMAb binding to at least some epitopes, either directly by forming 465 
part of such epitopes or indirectly by being proximal to them; 3) the glycosylation profile of 466 
natural E2 (i.e. E2 produced in HCV-infected human liver cells) is probably more similar to 467 
that of HEK293-derived sE2 than of Sf9-derived sE2; and 4) the HMAbs used in this study 468 
were derived from individuals naturally infected with HCV. A previous global epitope 469 
mapping study (7) found that mutation of certain E2 glycan sites, including glycan N10 470 
which is located in the E2 back layer near the mapped CBH-4B and CBH-4G binding sites 471 
(Figure 5) and shows reduced occupancy for Sf9-expressed sE2 (Figure 4), affects E2 472 
binding for these and other HMAbs. More revealing with respect to structural and functional 473 
integrity is the ability of Sf9- and HEK293-derived sE2 to bind the CD81 receptor with 474 
nearly identical KDs (Figure 6A and B). 475 
  As observed for recombinant HIV-1 envelope trimer produced in HEK293 cells (23), 476 
our LC-UV-MS/MS analysis of HEK293-derived sE2 revealed the presence of 477 
under-processed N-glycans that remain in oligomannose form (Man5–9GlcNAc2), possibly 478 
because the high density of glycans on the E2 surface imposes steric constraints that limit the 479 
actions glycan-processing enzymes in the Golgi compartment. We detected high mannose 480 
N-glycans at all 11 N-linked sites of HEK293-derived sE2. However, except at sites N8 and 481 
N11, the large majority of total identified glycoforms at the other nine N-linked sites were 482 
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complex type glycans, which are a hallmark of passage through the Golgi apparatus. In this 483 
respect, the overall glycosylation profile of HEK293-expressed sE2 resembles that of E1E2 484 
heterodimers associated with HCV pseudoparticles (HCVpp), which also display a majority 485 
of complex type glycans (16, 48). By contrast, E1E2 heterodimers associated with cell 486 
culture-derived HCV (HCVcc) contain a more balanced mixture of high mannose and 487 
complex type glycans. This difference suggests that both HEK293-expressed sE2 and 488 
HCVpp-associated E1E2 are more accessible to Golgi glycan-processing enzymes than 489 
HCVcc-associated E1E2, possibly because, in the HCVcc system, the E1E2 glycoprotein is 490 
associated with nascent viral particles as it travels through the secretory pathway, thereby 491 
restricting its exposure to Golgi enzymes.   492 
 In a previous study of HCV sE2 produced in mammalian (CHO) cells (49), complex 493 
glycans were detected at only 2 of 11 N-linked sites (N2 and N3); all 9 other sites were 494 
occupied by high or paucimannose N-glycans. By contrast, we identified complex glycans at 495 
all 11 N-linked sites. Moreover, a complex glycan was the most abundant glycoform at 6 of 496 
these 10 sites (N1, N3, N4, N5, N6, and N9) (Figure 3). These surprisingly large differences 497 
in glycosylation profiles may result from the use of different mammalian cell lines for sE2 498 
expression: HEK293 here versus CHO in the earlier study (49). The substantially higher 499 
content of complex N-glycans in HEK293-derived sE2 indicates more extensive processing 500 
of oligomannoses during passage of this particular glycoprotein through the Golgi 501 
compartment of HEK293 than CHO cells.  502 
 We found that differences in N-glycosylation of sE2 produced in HEK293 versus Sf9 503 
cells did not appreciably alter recognition by most HMAbs. Immunogenicity studies in mice 504 
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showed that similar polyclonal antibody responses were elicited against domains A–E by 505 
competition binding analysis. Neutralizing antibody titers showed that Sf9-derived sE2 was 506 
a more potent immunogen than HEK293-derived sE2 when tested against the homologous 507 
H77c isolate. However, both HEK293- and Sf9-derived sE2 elicited robust neutralizing 508 
antibody titers when tested against a diverse panel of HCVpp genotypes, although the overall 509 
titers trended higher for HEV293-derived sE2.   510 
  Our results differ markedly from those reported previously in a comparison of 511 
HEK293- and Drosophila S2-derived sE2 (31). In that study, the insect material was found to 512 
be a more potent immunogen against a diverse panel of heterologous isolates. Whether or not 513 
there is a difference in glycosylation between E2 proteins derived from Drosophila versus 514 
Spodoptera cells that could affect immunogenicity is an open question. At present, most 515 
knowledge of insect glycobiology comes from the Drosophila model (43), and it cannot be 516 
excluded that glycosylation in Spodoptera may differ in certain aspects. However, our 517 
LC-UV-MS/MS analysis of Sf9-expressed sE2 revealed a glycosylation pattern dominated 518 
by paucimannose N-glycans, with or without one or two core fucose residues, which is 519 
entirely consistent with what would be expected for sE2 produced in S2 cells (42, 43). 520 
Therefore, it is unlikely that differences in N-glycosylation can explain the apparent ability 521 
of S2-derived sE2, but not Sf9-derived sE2, to elicit higher titers of bNAbs against diverse 522 
HCV genotypes than HEK293-derived sE2 (31).  523 
  Several other factors may be responsible for the discrepancy between our results and 524 
those of Li et al. (31). One is the different mouse strains used here (CD-1) and in the Li et al. 525 
study (BALB/c). Although CD-1 mice are outbred and have more genetic diversity than 526 
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inbred BALB/c mice, this likely did not contribute to the differences seen between the two 527 
studies because in this study the B cell responses to sE2 are similar using CD-1 and BALB/c 528 
mice (data not shown). It is also possible that the different adjuvants used by us (SAS) and Li 529 
et al.  (31) (alum/CpG) significantly affected the immune response to otherwise very similar 530 
insect cell-derived sE2 glycoproteins. For example, in a study comparing enzymatically 531 
demannosylated HIV-1 gp120 produced in CHO cells with its untreated counterpart, 532 
demannosylation was found to increase immunogenicity in an adjuvant-dependent manner. 533 
Thus, when administered in alum, demannosylated gp120 was more immunogenic than the 534 
untreated glycoprotein, but this difference disappeared when Quil-A, a saponin-based 535 
adjuvant, was used (50). In this study, we used SAS as the adjuvant, which is an oil-in-water 536 
emulsion compared to alum/CpG used by Li et al. (31). It has been previously reported that 537 
innate and adaptive immune responses can differ between the two adjuvant systems 538 
depending on the antigen used, route of administration, and schedule (51). Nevertheless, 539 
both adjuvant systems are capable of eliciting robust B cell responses so this also may not 540 
account for the breadth of neutralization differences seen between the two studies. Another 541 
difference with the Li et al. study  and ours is that our sE2 protein was derived from the gt1a 542 
isolate, H77, while their sE2 was from the gt1b isolate, Con1b. These have 22% sequence 543 
divergence at the amino acid level, which may impact immunogenicity of specific epitopes 544 
or E2 overall; recent studies have demonstrated that HVR1 (amino acid divergence is 59% in 545 
that region between H77 and Con1b, with 16 out of 27 amino acids changed) and other E2 546 
sites are responsible for differences in neutralization sensitivity for sets of E2-targeting 547 
bnAbs (52, 53). Finally, we tested neutralization using HCVpp, whereas Li et al. (31) used 548 
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HCVcc. This difference is potentially significant because, as noted above, HCVpp and 549 
HCVcc have different glycosylation profiles (16, 48). Any one or any combination of the 550 
above differences could account for the discrepancies between the two studies.  551 
 While conceptually very appealing, the idea that altering glycans on viral envelope 552 
glycoproteins can actually yield superior immunogens for vaccine development remains to 553 
be demonstrated, despite considerable effort by a number of laboratories and some promising 554 
results. For example, although HIV-1 gp120 produced in Sf9 cells displayed increased 555 
binding to antibodies targeting the CD4 binding site (30), the new generation of HIV-1 556 
envelope trimers for vaccine use is expressed in mammalian, not insect, cells (54). Similarly, 557 
antigens based on HIV-1 envelope glycan deletion mutants have proved to be less effective 558 
than, or at best equivalent to, wild-type antigens at generating neutralizing antibody 559 
responses possessing both breadth and potency (17, 28, 55, 56). At present, selective 560 
deglycosylation of HIV-1 envelope trimers is under investigation as a strategy for activating 561 
naïve B cells expressing germline precursors of antibodies that target the CD4 binding site 562 
(25, 26). Given our findings that global alteration of HCV E2 glycosylation by expression in 563 
different cellular hosts did not appreciably affect antigenicity or overall immunogenicity, 564 
future efforts will focus on complete deletion, rather than only modification, of specific 565 
N-glycans in order to increase the exposure of virus neutralizing epitopes on E2 to the 566 
humoral immune system. For example, the removal of N-glycans at E2 positions 417 (N1) 567 
and 532 (N6) has led to increased sensitivity of the mutant isolates to neutralization by MAbs 568 
to antigenic domain E and B, respectively (14, 15). A focused effort to eliminate these and 569 
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other glycans that affect antibody binding to domains B, D and E might lead to an improved 570 
immunogen to elicit their associated bNAbs. 571 
 572 
  573 
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FIGURE LEGENDS 588 
Figure 1.  Expression of soluble HCV E2 (sE2) derived from mammalian (HEK293) and 589 
insect (Sf9) cells. (A) Schematic representation of sE2 expression cassettes used in 590 
mammalian (HEK293-sE2) and insect cell (Sf9-sE2) vectors. A sequence encoding sE2 591 
(amino acids 384–661) from genotype 1a (H77) was cloned into the vector pSecTag2 592 
in-frame with an immunoglobulin light chain κ signal peptide sequence and fused with a 593 
C-terminal His6 tag. Recombinant plasmid was used to transfect HEK293F cells. The same 594 
sequence was cloned into the baculovirus expression vector pAcGP67-B with a polyhedrin 595 
(Polh) promoter. The construct was transfected into Sf9 cells together with BaculoGold 596 
Linearized to produce sE2. (B) Superdex 200 size exclusion chromatography profile of 597 
HEK293-derived sE2 following HisTrap Ni2+-NTA affinity chromatography. Peak (red 598 
arrow) corresponding to monomeric sE2 was isolated for analytical and immunization 599 
studies. (C) Superdex 200 chromatography profile of Sf9-derived sE2 following HisTrap 600 
Ni2+-NTA chromatography. Peak (red arrow) corresponding to monomeric sE2 was isolated 601 
for all further experiments. Peak marked by red arrow corresponds to monomeric sE2. (D) 602 
Non-reducing SDS-PAGE (10%) of purified HEK293- and Sf9-derived sE2 proteins used for 603 
analytical characterization and immunization studies (Coomassie blue G-250 staining). (E) 604 
Western blot analysis of purified HEK293- and Sf9-derived sE2 proteins. Proteins were 605 
separated on SDS-PAGE (4–15%) after reduction by -mercaptoethanol and boiling for 10 606 
min. Proteins were then transferred onto a nitrocellulose membrane (Bio-Rad Laboratories). 607 
The membrane was probed with anti-HCV E2 HMAb HC33.1 (7) at 4.5 g/ml, followed by 608 
secondary goat anti-human IgG-HRP conjugate at 1:5000 dilution.  609 
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 610 
Figure 2.  Representative ESI-MS of chymotryptic peptide FNSSGCPER (amino acids 447–611 
455) from HCV sE2. (A) Glycopeptide heterogeneity observed on FNSSGCPER peptide 612 
from HEK293-expressed sE2 (RA ≥ 1% listed in spectrum and RA ≥ 0.1% listed in table). 613 
(B) Glycopeptide heterogeneity observed on FNSSGCPER peptide in Sf9-expressed E2 (RA 614 
≥ 1% listed in spectrum and RA ≥ 0.1% listed in table). Note that only doubly charged 615 
glycopeptides are labeled in the spectrum for clarity for both panels (A) and (B).   616 
 617 
Figure 3. Schematic representation of HCV sE2 chymotryptic glycopeptides depicted with 618 
the most abundant glycan observed during LC-MS analysis of HEK293 (top glycoform) and 619 
Sf9 (bottom glycoform) sE2 proteins. In cases where the most abundant proteoform was 620 
aglycosylated, the most abundant glycosylated form was used (Supplementary Table 1). 621 
“…” represents flanking amino acid sequence not shown for brevity. N-acetylglucosamine, 622 
blue squares; fucose, red triangles; mannose, green circles; galactose, yellow circles; sialic 623 
acid, purple diamonds.   624 
 625 
Figure 4. Comparison of percent glycosylation of N-glycan sites for mammalian 626 
cell-expressed (HEK293) and insect cell-expressed (Sf9) sE2 glycoproteins. Most N-glycan 627 
sites are fully or nearly fully glycosylated, with the exception of N10 (N623) and N11 628 
(N645), where N-glycan sites have relatively lower glycan occupancy for Sf9-derived eE2, 629 
whereas glycan N3 (N430) has lower glycan occupancy in HEK293 cells.  630 
 631 
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Figure 5. Modeled structural impact of glycosylation for HEK293- versus Sf9-expressed 632 
sE2. Structures of the most abundant glycoforms for HEK293 (A, C) and Sf9 (B, D) sE2 633 
were modeled using Rosetta (36) onto the E2 core crystal structure (PDB code 4MWF) (35). 634 
Glycans are shown as tan, slate, and yellow sticks and labeled, and E2 is shown as surface 635 
and cartoon, with views of E2 front layer (A, B) and back layer (C, D). For reference, 636 
neutralizing antibody footprints on E2 are colored blue, magenta, and green, based on the 637 
epitope-bound crystallographic structures of HC33.1 (PDB code 4XVJ), AR3C (PDB code 638 
4MWF), and HC84.26.5D (PDB code 4Z0X) antibodies, respectively. Colored E2 residues 639 
indicate those within 5.0 Å of bound antibody, and shared E2 contact residues between 640 
antibodies are colored according to antibody with highest E2 residue burial. Residues from 641 
antigenic domain E were modeled at the N-terminus of the E2 core structure using Rosetta 642 
(36). Glycan N5, which is within a region that is missing from the E2 core crystal structure, is 643 
not shown.  644 
  645 
Figure 6. BLI analysis of CD81 and antibody binding to HCV sE2 from HEK293 and Sf9 646 
expression systems. (A) Sensograms (left) for CD81 binding to immobilized 647 
HEK293-derived sE2. CD81 concentrations were 5000, 4000, 2500, 2000, 1250, 1000, 625, 648 
500, 312.5, 250, 156.25, 125, 78.125, 62.5, 39.06 nM. Steady state analysis graph (right) 649 
gave KD = 510 ± 22 nM. (B) Sensograms (right) for CD81 binding to immobilized 650 
Sf9-derived sE2. CD81 concentrations were 5000, 4000, 2500, 2000, 1250, 1000, 625, 500, 651 
312.5, 250, 156.25, 125, 78.125, 62.5, 39.06 nM. Steady state analysis graph (right) gave KD 652 
= 440 ± 38 nM. (C) Sensograms (left) for HC84.26 (domain D-specific HMAb) binding to 653 
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immobilized HEK293-derived sE2. HC84.26 concentrations were 5, 2.5, 1.25, 0.625, 0.3125 654 
and 0.156 nM. Steady state analysis graph (right) gave KD = 1.8 ± 0.5 nM. (D) Sensograms 655 
(left) for HC84.26 binding to immobilized Sf9-derived sE2. HC84.26 concentrations were 656 
10, 5, 2.5, 0.625, 0.3125 and 0.156 nM. Steady state analysis graph (right) gave KD = 2.7 ± 657 
0.8 nM. (E) Sensograms (left) for HC84.24 (domain D-specific HMAb) binding to 658 
immobilized HEK293-derived sE2. HC84.24 concentrations were 20, 15, 10, 7.5, 5, 3.75, 659 
2.5, 1.875, 0.9375, 0.625, 0.469, 0.3125, 0.234 and 0.156 nM. Steady state analysis graph 660 
(right) gave KD = 1.9 ± 0.3 nM. (F) Sensograms (left) for HC84.24 binding to immobilized 661 
Sf9-derived sE2. HC84.24 concentrations were 1000, 750, 500, 375, 250, 187.5, 125, 93.8, 662 
62.5, 46.9, 31.6 and 23.4 nM. Steady state analysis graph (right) gave KD = 1200 ± 290 nM. 663 
(G) Sensograms (left) for CBH-4B (domain A-specific HMAb) binding to immobilized 664 
HEK293-derived sE2. CBH-4B concentrations were 100, 50, 25, 12.5, 6.25 and 3.125 nM. 665 
Steady state analysis graph (right) gave KD = 11 ± 1.7 nM. (H) Sensograms (left) for 666 
CBH-4B binding to immobilized Sf9-derived sE2. CBH-4B concentrations were 50, 25, 667 
12.5, 6.25 and 3.13 nM. Steady state analysis graph (right) gave KD = 120 ± 11 nM. (I) 668 
Sensograms (left) for HCV1 (domain E-specific HMAb) binding to immobilized 669 
HEK293-derived sE2. HCV1 concentrations were 200, 150, 100, 75, 50, 37.5 and 25 nM. 670 
Steady state analysis graph (right) gave KD = 36 ± 3.0 nM. (J) Sensograms (left) for HCV1 671 
binding to immobilized Sf9-derived sE2. HCV1 concentrations were 25, 20, 15, 10, 5, 2.5, 672 
1.25 and 0.078 nM. Steady state analysis graph (right) gave KD = 9.3 ± 2.0 nM. (K) 673 
Sensograms (left) for HC-1 (domain B-specific HMAb) binding to immobilized 674 
HEK293-derived sE2. HC-1 concentrations were 200, 175, 150, 75, 50, 37.5, 25, 12.5, 6.25, 675 
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3.125, 1.56, 0.78, 0.39 and 0.195 nM. Steady state analysis graph (right) gave KD = 65 ± 10 676 
nM. (L) Sensograms (left) for HC-1 binding to immobilized Sf9-derived sE2. HC-1 677 
concentrations were 200, 175, 150, 75, 50, 37.5, 25, 12.5, 6.25, 3.125, 1.56, 0.78, 0.39 and 678 
0.195 nM. Steady state analysis graph (right) gave KD = 69 ± 6.5 nM. 679 
 680 
Figure 7.  Competition binding analysis of immune sera corresponding to domains A–E. (A) 681 
HEK293-derived sE2 immunized CD-1 mice. (B) Sf9-derived sE2 immunized CD-1 mice. 682 
Sera from day 42 were tested for binding competition using antibodies representing antigenic 683 
domains A–E (7), with mean percent competition shown with black bars. All values were 684 
normalized by subtracting percent competition values from control (pre-immune) sera, 685 
which were measured individually for each mouse. Antibodies tested were CBH-4B (domain 686 
A), HC-1 (domain B), CBH-7 (domain C), HC84.26 (domain D), and HC33.4 (domain E).  687 
 688 
Figure 8.  Kinetics and magnitude of nAb titers against homologous H77 strain. HCV 689 
pseudoparticles (HCVpp) were generated by co-transfection of HEK293T cells with HCV 690 
E1E2, MLV Gag-Pol packaging vector, and luciferase reporter plasmid as previously 691 
described (40). Titrations of HCVpp were performed on Hep3B cells, and luciferase activity 692 
measured in relative light units (RLUs) using SpectraMax M3. Percent neutralization was 693 
calculated as 100 × [1−yRLUtest/RLUcontrol)]. nAb titers in animal sera are reported as 694 
50% inhibitory dilution (ID50) values, calculated using nonlinear curve fitting in GraphPad 695 
Prism. Neutralization kinetics were determined by inhibition of homologous HCVpp (H77) 696 
using serial dilutions of serum collected on days 28, 35, 42 and 49. Blue dots represent serum 697 
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samples from HEK293 sE2 immunized mice, green dots represent samples from Sf9 sE2 698 
immunized mice, and black bars indicate geometric means. One Sf9 E2 immunized mouse 699 
had insufficient day 35 sera available for testing, thus four rather than five points are shown 700 
for that group and day. P-values were determined using GraphPad Prism 7 with 701 
Kruskal-Wallis ANOVA, and significant p-values between immunized groups are indicated 702 
(*: p < 0.05). 703 
 704 
Figure 9.  Breadth of neutralization against HCV genotypes 1–6. HCVpp generated with 705 
functional E1E2 clones derived from six diverse HCV genotypes, gt1a (H77c, UNKP1.1.1), 706 
gt1b (UNKP1.20.3, UNKP1.21.2), gt2a (J6, JFH), gt2b (UNKP2.4.1), gt2i (UNKP2.1.2), gt3 707 
(UNKP3.2.2), gt4 (UNKP4.2.1), gt5 (UNKP5.1.1), and gt6 (UNKP6.1.1), were assessed for 708 
their neutralization sensitivity (50% neutralization titer; ID50) to CD-1 mouse serum samples 709 
immunized with HEK293-derived sE2 (blue dots) and Sf9-derived sE2 (green dots), using 710 
HuH7 target cells. Geometric mean ID50 values are shown as black bars. P-values were 711 
determined using GraphPad Prism 7 with Kruskal-Wallis ANOVA, and significant p-values 712 
between immunized groups are indicated (*: p < 0.05). 713 
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Figure 2. 729 
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Figure 3. 745 
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Figure 4. 748 
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Figure 5. 751 
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Figure 6.   755 
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Figure 7. 756 
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Figure 8. 759 
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Figure 9. 762 
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Table 1. Analytical gradient 
     
    % B    MS Data  
 Time (mL/min) (0.1 % FA in ACN) Divert Valve Collection 
 0 0.25 1 Waste No 
 2 0.25 1 MS Yes 
 6 0.25 10 MS Yes 
 70 0.25 35 Waste No 
 72 0.25 90 Waste No 
 77 0.25 90 Waste No 
 79 0.25 1 Waste No 
 81 0.25 1 Waste No 
 83.5 0.25 10 Waste No 
 91.5 0.25 45 Waste No 
 93 0.25 90 Waste No 
 99 0.25 90 Waste No 
 101 0.25 1 Waste No 
 115 0.25 1 Waste No 
 
  765 
 o
n
 January 25, 2019 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
45 
Table 2.  Calculated E2 percent surface occlusion by most abundant N-glycans from HEK293 766 
and Sf9 expression systems modeled onto the E2 core structure.  767 
Probe 
Radius (Å) 
HEK293 Sf9 
1.4 20% 21% 
5 49% 43% 
10 64% 55% 
 768 
  769 
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Table 3. Affinities of HEK293 sE2 and Sf9 sE2 for CD81 and HMAbs  770 
 771
 HEK293 sE2 Sf9 sE2 
Ligand KD (nM) R
2
 KD (nM) R
2
 
CD81      510 ± 22   0.997      440 ± 38   0.984 
HC84.26a       1.8 ± 0.5    0.965       2.7 ± 0.8   0.965 
HC84.24a       1.9 ± 0.3   0.962    1200 ± 29   0.980 
CBH-4Bb        11 ± 1.7   0.971      120 ± 11   0.926 
CBH-4Gb      120 ± 33   0.949 no binding – 
HCV1c        36 ± 3.0   0.985       9.3 ± 2.0   0.946 
HC33.1c        50 ± 9.9   0.979        47 ± 9.9   0.927 
HC-1d        65 ± 1.0   0.980        69 ± 6.5   0.993 
HC-11d       7.0 ± 1.3   0.975        25 ± 4.4   0.974 
aSpecific for antigenic domain D. bSpecific for antigenic domain A.  772 
cSpecific for antigenic domain E. dSpecific for antigenic domain B.  773 
  774 
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